fizkes
- Alkermes is down ~31% in after-hours trading Wednesday after reporting phase 2 study results of alixorexton for narcolepsy type 2.
- The Vibrance-2 trial met its dual primary endpoints: improvement from baseline compared to placebo on the Maintenance of Wakefulness Test and
